Application of lncMCL1 in regulating pyroptosis degree of neuronal cells and relieving and treating related diseases

By overexpressing lncMCL1 in neuronal cells, the NLRP3 inflammasome signaling pathway was regulated, and neuronal loss and frequent seizures in refractory epilepsy were solved, effective inhibition of neuronal cell pyroptosis and inflammatory necrosis was achieved, and hippocampal tissue was protected.

CN120267856AActive Publication Date: 2025-07-08BEIJING NEUROSURGICAL INST
4 Cites 0 Cited by

Patent Information

Application Number
CN202510733315.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-06-04
Publication Date
2025-07-08
Estimated Expiration
2045-06-04

AI Technical Summary

Technical Problem

The prior art is difficult to effectively regulate neuronal cell pyroptosis, resulting in frequent seizures and neuronal loss of refractory epilepsy such as temporal lobe epilepsy, especially NLRP3 inflammasome activation and hyperinflammatory response in hippocampal tissue.

Method used

By enhancing or regulating the expression of lncMCL1 in neuronal cells, nucleic acid molecules, recombinant vectors or recombinant microorganisms encoding lncMCL1, especially through adeno-associated viral vectors, inhibiting NLRP3 inflammasome signaling pathways and inflammatory necrosis.

Benefits of technology

It significantly reduces the degree of pyroptosis and inflammatory necrosis of neuronal cells, reduces the release of inflammatory factors, protects the neurons of hippocampal tissue, reduces the frequency of epilepsy, and reduces the symptoms of epilepsy.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention provides application of lncMCL1 in regulating and controlling the pyroptosis degree of neuronal cells and relieving and treating related diseases, and relates to the technical field of biological medicine. The invention specifically discloses regulation and control of pyroptosis of neuronal cells by enhancing or reducing expression of lncMCL1, and further discloses application of a substance for regulating and controlling expression enhancement of lncMCL1 in preparation of drugs for relieving and treating neuronal function deficiency related diseases, especially epilepsy. In-vivo experiments and in-vitro experiments prove that lncMCL1 can be used as a key regulatory factor for pyroptosis of neuronal cells by regulating inflammatory response of the neuronal cells, and can effectively regulate pyroptosis of the neuronal cells and relieve and treat diseases related to neuronal function deficiency.
Need to check novelty before this filing date? Find Prior Art